Advanced Therapies in Europe

Size: px
Start display at page:

Download "Advanced Therapies in Europe"

Transcription

1 Advanced Therapies in Europe 1

2 ATMPs in Europe ( ) ~ 500 clinical trials using ATMPs in EU ~ 270 ATMP classifications 18 MAAs reviewed ~ 250 scientific advice requests 9 ATMPs approved 2 3 withdrawn 1 Suspended Market 5 licensed ATMPs

3 Challenges in ATMP s availability to Patients Learning from previous MAAs Quality Non-clinical Clinical Regulatory Patient access (8 years) q 18 MAAs reviewed or under review q 9 products approved q 3 withdrawn, 1 suspended, 1 negative opinion q 5 licensed ATMPs q Approx. 111 patients treated HTA, Price and reimbursement 3 ATMPs are complex products to develop, manufacture, evaluate and make available to patients

4 Challenges - areas Quality Nonclinical Other Clinical 4

5 European Commission EMA Action Plan on ATMPs 5 Published 20 October 2017 Builds on the issues identified at the Multistakeholder workshop Concrete actions to improve the regulatory framework for ATMPs (within the existing legal framework) Goal: increase the opportunity for patients to be treated with novel therapies and to promote innovation, investment and competitiveness of the EU biotech sector

6 Scientific Advice for ATMPs 250 SA procedures started CAT involved (routinely) in all SA for ATMPs Increase in SA s for ATMPs over period (especially for GTMP) SA requests until July

7 Of the 121 valid applications received, 35 were for ATMPs (29%). Out of the 28 PRIME granted, 13 were for ATMPs (46%): - 12 are GTMPs, 1 CTMP - 7 Oncology, 4 Haematology, 1 Transplantation, 1 Neurology 7

8 ATMPs in clinical trials Commercial vs non-profit sponsor Stage of development 8

9 EMA expert meeting on genome editing 18 October The European Medicines Agency (EMA) convened an expert meeting on genome editing technologies. The three sessions focussed on: 1/ Genome editing and technologies: state of the art and future outlook 2/ Application of genome editing by Academia 3/ Case studies using genome editing technologies Outcome: Discussion on scientific and regulatory opportunities and challenges of medicinal product development using genome editing technologies. Report envisaged in Conclusion: An active research field with promising pipeline Limited CT developments worldwide Some challenges in developing these products to be addressed What we can and will do: Continue to listen to developers Support development by fostering early dialogue Cooperation to facilitate marketing authorisation and access to patients, at EU and international level 9

10 10

11 Take home messages Regulatory and Scientific Process Wide engagement with stakeholders Streamline EMA internal regulatory processes + Promote use of early access tools + Harmonise and guide on application documents & national requirements + Raise awareness of regulatory process, early engagement and collaboration + Develop different models of collaboration and engagement with the wider community of ATMP stakeholders Academia Payers INVESTORS Committee Advanced Therapies (CAT) 11 Patients

12 Thank you for your attention With thanks to: Veronika Jekerle, Patrick Celis and Falk Ehmann Follow us Ana Hidalgo-Simon European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website

13 Back up slides

14 Quality challenges 14 Donation, procurement and testing according to Dir. 2004/23/EC (2006/86/EC) Variability of the starting material (autologous & allogeneic) GMP requirements for early manufacturing steps (e.g. cell extraction from biopsies) Excipients/reagents qualified for clinical use (e.g. growth factors, cytokines): EDQM General monograph Raw materials for the production of cellbased and gene therapy medicinal products Characterisation methods and potency Comparability Medical device or structural component & administration device

15 Non-clinical challenges Suitability of animal models (species specificity) Predictability for safety (i.e. long-term safety) Homologous model / disease model (efficacy/ proof of concept) Large animal model necessary? (surgical procedure, tissue regeneration) GLP environment (for toxicity studies) Biodistribution & methods for tracking cells (systemic applications) 15

16 Clinical challenges Long-term efficacy Safety Ø Ø Ø Ø Ø Clinical control available/feasible/ethical Standardised collection & delivery procedure Dose available & justified Duration of follow-up (efficacy/safety) Traceability 16

17 Additional elements Growing innovation ecosystems in the EU Need to raise awareness of regulatory process among a diverse set of stakeholders, sometimes outside the classic sphere of influence of regulators Early engagement and collaboration needed: with developers and users Patient access: develop different models for reimbursement and payment 17

18 Framework of collaboration with academia Purpose Aims to formalise and structure the collaboration between the Agency and Academia in the wider context of the European Regulatory System for Medicines Scope Framework will cover collaboration between Agency and academia, covering areas of common interest in relation to medicines for human and veterinary use. Queries relating to a specific product and/or regulatory procedure fall outside the scope of this framework Implementation Action plan, monitoring and reporting Key elements Mapping of academic entities with an interest in the regulatory activities Evolution of available expertise to keep pace with advances in scientific knowledge Identifying opportunities to promote research and knowledge generation Promoting and reinforcing dialogue through effective communication Monitoring progress and output of the cooperation with academia 18

19 International dimension Until recently: Product development was very regional, although the need for alignment of the scientific and regulatory requirements was identified early on (ATMP cluster started in 2008, IPRF cell therapy and gene therapy groups since 2011 / 2012 respectively) Situation today: Most Regulatory Authorities have by now a clear legal framework for the approval of Gene and Cell-based Medicines Limited approvals of ATMPs (worldwide), but active pipeline (development of new products, clinical trials) Already here: 19 CAR-T s: worldwide development, approvals in US, ongoing evaluations in EU, submissions to other authorities Gene therapy products: (ophthalmologic indication, orphan) approved US Tissue engineered product: e.g. MACI approved in US and Spherox approved in the EU IND / CTA (Scientific advice) for same products Direction of travel: Strengthening of the EMA-FDA interactions

20 Several elements under construction l GMP for ATMP published in November l l Application of GLP through development clarification published in CTFA and EMA websites in 2017 ATIMP Guideline - drafting ongoing l Revised S&E follow-up / Risk Management Plan guideline drafting ongoing l l l Q&A for minimally manipulated ATMPs - published Revised definition for orphan designation published Revised GM Cell Guideline Concept paper consultation closed l Comparability of ATMPs (Q&A) to start

Five years as EMA Liaison at US FDA

Five years as EMA Liaison at US FDA Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines

More information

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development

More information

Monthly statistics report: December 2017

Monthly statistics report: December 2017 19 January 2018 EMA/39932/2018 Information Management Division Medicinal products for human use (cumulative figures for the year to date) This document provides current information related to the volume

More information

ABPI response to European Commission consultation on advanced therapy medicinal products

ABPI response to European Commission consultation on advanced therapy medicinal products ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal

More information

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach 3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the

More information

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member

More information

ACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm

ACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human

More information

Work plan for the GMP/GDP Inspectors Working Group for 2017

Work plan for the GMP/GDP Inspectors Working Group for 2017 13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings

More information

Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)

Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) 6 October 2016 EMA/CVMP/ADVENT/630299/2014 Rev.2 Committee for Medicinal Products for Veterinary Use (CVMP) Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel

More information

CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS

CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS Maria Cristina Galli, Ph.D. Istituto Superiore di Sanità Roma, Italy EATRIS ATMP platform chair ISCT 2016 Global Regulatory Perspective Workshop

More information

EU Update on Regulatory Developments

EU Update on Regulatory Developments EU Update on Regulatory Developments Pascal Venneugues European Medicines Agency CASSS CMC Strategy Forum Europe Copenhagen, 4-6 May 2015 An agency of the European Union Overview International cooperation

More information

GMO Technology Conference

GMO Technology Conference GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October

More information

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs 9 November 2017 EMA/CHMP/CVMP/3Rs/94436/2014 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Guidance for individual laboratories for transfer

More information

Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016)

Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016) 11 January 2018 Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016) Comments from: Name of organisation or individual

More information

Orphan designation in the EU

Orphan designation in the EU Orphan designation in the EU EURORDIS summer school Barcelona, June 2013 Presented by: Jordi Llinares Head of Orphan Medicines An agency of the European Union Outline Overview orphan designation Procedure

More information

Recommendations on eligibility to PRIME scheme

Recommendations on eligibility to PRIME scheme 1 June 2016 EMA/345382/2016 Press office Adopted at the CHMP meeting of 23-26 May 2016 During its May 2016 meeting, the CHMP reviewed 18 recommendations for eligibility to PRIME: 4 were granted and 14

More information

Update on EMA Brexit preparedness

Update on EMA Brexit preparedness Update on EMA Brexit preparedness SME Office Info Day on Supporting innovative medicines development and early access 17 November 2017 Presented by Anthony Humphreys An agency of the European Union EMA

More information

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board 18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP)

EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP) EMA / FDA efforts towards Regulatory Harmonisation - Transatlantic Trade and Investment Partnership (TTIP) European Health Forum - 3 rd October 2013 Falk Ehmann MD, PhD European Medicines Agency - London

More information

EU Portal and Database Update

EU Portal and Database Update EU Portal and Database Update TOPRA 4 October 2017 Presented by Noémie Manent on 4 October 2017 Committees and Inspections Department An agency of the European Union Table of content EMA Portal and Database

More information

Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None

Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None EAHP March 2016 Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4 Dr. Lenka Taylor Pharmacy University Hospital Heidelberg Disclosure Relevant Financial Relationships

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 9 November 2017 EMA/CHMP/CVMP/3Rs/83712/2017 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Overview of comments received on 'Guidance

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 17 December 2015 EMA/839636/2015 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Reflection paper on the chemical structure and properties criteria to be considered

More information

Supporting Innovation through Scientific Advice

Supporting Innovation through Scientific Advice Supporting Innovation through Scientific Advice PEARRL Regulatory Science Symposium, 21 st June 2017, University College Cork HPRA Dr Peter Kiely Disclaimer All views expressed in this presentation are

More information

Agenzia Italiana del Farmaco

Agenzia Italiana del Farmaco Agenzia Italiana del Farmaco European Regulation on Advanced Therapies Cristina Pintus Head of European Relations Unit and Coordinator of the Advanced Therapy Project Italian Medicines Agency Proposal

More information

Quality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017

Quality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017 Quality Systems Indian Pharmaceutical Alliance Advanced GMP Workshops 2017 Presented by Patrick Costello on November 2017 Principal Scientific Administrator Manufacturing & Quality Compliance An agency

More information

Pharmacovigilance. An agency of the European Union

Pharmacovigilance. An agency of the European Union Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related

More information

SPOR data management services - high level changes

SPOR data management services - high level changes 6 July 2017 EMA/551661/2016 version 3 Information Management Division Table of contents 1. Introduction... 2 2. New solutions for access and use of SPOR data... 2 2.1. RMS backward compatibility... 2 2.2.

More information

Regulating Cell Therapy: An Ex-Regulators Perspective

Regulating Cell Therapy: An Ex-Regulators Perspective Regulating Cell Therapy: An Ex-Regulators Perspective Christopher A Bravery 1 Introduction Regulation of Healthcare products in the EU What is cell therapy? How does it fit into existing framework? Is

More information

Pharmacovigilance: Information systems and services

Pharmacovigilance: Information systems and services Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver

More information

Adoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011

Adoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011 18 October 2012 EMA/651649/2010 Committee for Medicinal Products for Human Use Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative,

More information

Global Regulatory Perspective Workshop

Global Regulatory Perspective Workshop Global Regulatory Perspective Workshop ISCT meeting Singapore 25 May 2016 Dr Nicolas FERRY ANSM, France Avertissement Lien d intérêt : personnel salarié de l ANSM (opérateur de l Etat). La présente intervention

More information

Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products

Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products 02 May 2013.. Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products 7 Westferry Circus Canary Wharf London

More information

Clinical Trial Safety Reporting requirements

Clinical Trial Safety Reporting requirements Clinical Trial Safety Reporting requirements SME info day 20 Mar 2017 Presented by Sophia Mylona Clinical & Non-clinical Compliance, European Medicines Agency An agency of the European Union Article Regulation

More information

Non-clinical Assessment Requirements

Non-clinical Assessment Requirements Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance

More information

Survey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia

Survey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia 20 October 2016 Stakeholders and Communication Division Survey report European Medicines Agency (EMA) consultation on the proposal of a collaboration framework with academia 30 Churchill Place Canary Wharf

More information

Questions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility

Questions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility 15 June 2017 EMA/CVMP/ADVENT/751229/2016 Committee for Medicinal Products for Veterinary Use (CVMP) Questions and Answers on allogenic stem cell-based products for veterinary use: Draft problem statement

More information

Draft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September

Draft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September 23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis

More information

Report from the Paediatric Committee on its first anniversary

Report from the Paediatric Committee on its first anniversary European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)

More information

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development 1 2 3 24 June 2010 EMA/CHMP/641298/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug

More information

EMA action plan related to the European Commission s recommendations on product information 1

EMA action plan related to the European Commission s recommendations on product information 1 14 November 2017 EMA/680018/2017 Stakeholders and Communication Division EMA action plan related to the European Commission s recommendations on product information 1 The European Medicines Agency (EMA)

More information

Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation

Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation 2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for

More information

Draft agreed by SWP, vswp and GMP/GDP Inspectors WG September Adopted by CVMP for release for consultation 8 November 2016

Draft agreed by SWP, vswp and GMP/GDP Inspectors WG September Adopted by CVMP for release for consultation 8 November 2016 15 December 2016 EMA/CHMP/CVMP/SWP/463311/2016 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Questions and answers on implementation of

More information

Regulatory utilization of Flexible Regulatory Pathways to meet unmet medical need

Regulatory utilization of Flexible Regulatory Pathways to meet unmet medical need Median approval time (days) 170 356 Regulatory utilization of Flexible Regulatory Pathways to meet unmet medical need Session: UNMET (MEDICAL) NEED: SHOULD STAKEHOLDERS ALIGN ON A DEFINITION? Neil McAuslane

More information

Work programme October 2017 EMA/583016/2016 Rev.1 1 Executive Director. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

Work programme October 2017 EMA/583016/2016 Rev.1 1 Executive Director. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom 9 October 2017 EMA/583016/2016 Rev.1 1 Executive Director 1 Project added to 2017 work programme, chapter 4: Support and governance activities 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

EU perspective: European procedure for Qualification of novel methodologies for medicine development. Elmer Schabel MD

EU perspective: European procedure for Qualification of novel methodologies for medicine development. Elmer Schabel MD EU perspective: European procedure for Qualification of novel methodologies for medicine development Elmer Schabel MD Nothing to disclose See: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/ex

More information

Update on Real World Evidence Data Collection

Update on Real World Evidence Data Collection Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large

More information

Adaptive Pathways and PRIME: A True Acceleration of Drug Development and Approval?

Adaptive Pathways and PRIME: A True Acceleration of Drug Development and Approval? BERICHTE + ANALYSEN + MEINUNGEN European Medicines Agency's Initiatives Adaptive Pathways and PRIME: A True Acceleration of Drug Development and Approval? The European Medicines Agency (EMA) has launched

More information

EU Regulation Review: challenges and opportunities for industry

EU Regulation Review: challenges and opportunities for industry EU Regulation Review: challenges and opportunities for industry Mia Bengtström, Pharma Industry Finland Nordic Pediatric Conference June 13,2017 Paediatric Regulation Consultation: EFPIA s answers general

More information

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014 20 January 2015 EMA/641479/2014 Compliance and Inspections Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

More information

COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)

COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) European Medicines Agency London, 26 April 2007 Doc. Ref. EMEA/CHMP/GTWP/367513/2006 COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) CONCEPT PAPER ON The development of a Guideline on clinical

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS

More information

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation

More information

The European Medicines Agency: a model of patient/consumer interaction

The European Medicines Agency: a model of patient/consumer interaction The European Medicines Agency: a model of patient/consumer interaction V International Conference on patient safety Juan García Burgos Head of Public Information and Stakeholder Networking - Medical Information

More information

Mandate and objectives for the EMA Working Party on Quality Review of Documents (QRD)

Mandate and objectives for the EMA Working Party on Quality Review of Documents (QRD) 1 July 2014 EMA/403106/2014 Mandate and objectives for the EMA Working Party on Quality Review of Documents 1. General considerations The European Medicines Agency (EMA) created an ad hoc Working Group

More information

Escher-ATMP Project Results

Escher-ATMP Project Results EBE-EFPIA Initiative Escher-ATMP Project Results Renske ten Ham, MSc Division of Pharmacoepidemiology and Clinical Pharmacology - Utrecht University Escher-ATMP Project Overall Aim: Examine factors associated

More information

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives

More information

PACT. PACT Program. Production Assistance for Cellular Therapies

PACT. PACT Program. Production Assistance for Cellular Therapies PACT Production Assistance for Cellular Therapies University of Wisconsin PACT-sponsored Workshop Developing Cellular Therapies: From Preclinical Safety To Clinical Evaluation Tuesday, April 09, 2013 Robert

More information

Medical Literature Monitoring

Medical Literature Monitoring Medical Literature Monitoring 5 th Industry Platform on the implementation of EU pharmacovigilance legislation Presented by Tom Paternoster-Howe on 15 September 2015 EMA/Information Management/Data Standardisation

More information

Workshop on Access to and Uptake of Biosimilar Medicinal Products

Workshop on Access to and Uptake of Biosimilar Medicinal Products EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to

More information

27 September Introduction

27 September Introduction 27 September 2017 Possible solutions to improve the European regulatory procedures for clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

More information

Regulatory Requirements for CRISPR Therapeutics. Bill Lundberg, MD February 2017

Regulatory Requirements for CRISPR Therapeutics. Bill Lundberg, MD February 2017 Regulatory Requirements for CRISPR Therapeutics Bill Lundberg, MD February 2017 Forward Looking Statements This document contains forward-looking statements within the meaning of the safe harbor provisions

More information

Brexit Guidance for Stakeholders Human and veterinary medicines

Brexit Guidance for Stakeholders Human and veterinary medicines Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject

More information

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE: Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

Regulatory Considerations and Trends Europe and the U.S.

Regulatory Considerations and Trends Europe and the U.S. Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products

More information

The challenges of potency assay development for cell-based medicinal products in Europe

The challenges of potency assay development for cell-based medicinal products in Europe Focus Advanced therapies 5 The challenges of potency assay development for cell-based medicinal products in Europe Authors Valerie Pimpaneau, Senior Director, Voisin Consulting Life Sciences; François

More information

Guide to Scientific and Regulatory Advice for GXP activities

Guide to Scientific and Regulatory Advice for GXP activities Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

GMP Specific Considerations for ATMPs

GMP Specific Considerations for ATMPs uniqure 29. Oktober 2015 EMA / EuropaBio Information Day GMP Specific Considerations for ATMPs Alec Orphanidis Senior Vice President, Global Commercial Operations uniqure (Charmaine Augustinus-Lever Dir.

More information

European Directorate for the Quality of Medicines & HealthCare (EDQM)

European Directorate for the Quality of Medicines & HealthCare (EDQM) European Directorate for the Quality of Medicines & HealthCare (EDQM) INTERNATIONAL REGULATORY FORUM OF HUMAN CELL THERAPY AND GENE THERAPY PRODUCTS 16 MARCH 2016, OSAKA, JAPAN Dr Stephen J. Wicks Scientific

More information

EU Perspective on Regulatory Issues for Biologics

EU Perspective on Regulatory Issues for Biologics Oncology Biologics Development Primer 29 February 2008 Robert Charnas Disclosure Employee and shareholder of Amgen, Inc. Thousand Oaks, CA Worked in Basel, Switzerland for 19 Years and dealt with European

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office

More information

Is there a need for a new regulatory pathway for biologics?

Is there a need for a new regulatory pathway for biologics? Is there a need for a new regulatory pathway for biologics? AT Europe 2017 Brussels 16 March 2017 Alan Fauconnier Disclaimer Alan Fauconnier is quality assessor at the Federal Agency for Medicines and

More information

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure 11 December 2017 EMA/821278/2015 Human Medicines Research and Development Support European Medicines Agency pre-authorisation procedural advice for users of the This integrated version has been created

More information

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO) Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of

More information

Implementing the Directive - from the Swedish Perspective. Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials

Implementing the Directive - from the Swedish Perspective. Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials Implementing the Directive - from the Swedish Perspective Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials Previous system in Sweden CA (LVFS 1996:17) Approval of applications

More information

1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States

1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European

More information

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing

More information

Overview of comments received on 'Draft Guideline on manufacture of the finished dosage form'

Overview of comments received on 'Draft Guideline on manufacture of the finished dosage form' 14 July 2017 EMA/CHMP/QWP/104223/2016 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Draft Guideline on manufacture of the finished dosage form' (EMA/CHMP/QWP/245074)

More information

Commission. Product. Decision. Information issued on. Issued 2 / affected 3 amended on. 28/09/2017 SmPC, Labelling and PL

Commission. Product. Decision. Information issued on. Issued 2 / affected 3 amended on. 28/09/2017 SmPC, Labelling and PL Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification 1 Decision Information issued on Issued 2 / affected

More information

Blood procurement: Process development, clinical trials and the market

Blood procurement: Process development, clinical trials and the market Teaching your cells to treat your disease Blood procurement: Process development, clinical trials and the market Christelle Boniface, MSc. Miguel Forte, MD PhD ISCT annual meeting 2016, 25 May 2016 1 Disclaimer

More information

Centralised Procedure and Scientific Advice: an Overview

Centralised Procedure and Scientific Advice: an Overview Centralised Procedure and Scientific Advice: an Overview Andrea Laslop Head of Scientific Office AGES Medizinmarktaufsicht AGES Vienna 30/01/2018 Austrian Federal Office for Safety in Health Care www.basg.gv.at

More information

Submission of comments on the Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014)

Submission of comments on the Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014) 31 August 2015 Submission of comments on the Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014) Comments from: Name of organisation or

More information

Nanotechnology and Advanced Materials for more effective Healthcare

Nanotechnology and Advanced Materials for more effective Healthcare Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics

More information

Questions and answers on the 'Guideline on the limits of genotoxic impurities'

Questions and answers on the 'Guideline on the limits of genotoxic impurities' 23 September 2010 EMA/CHMP/SWP/431994/2007 Rev. 3 Committee for Medicinal Products for Human Use (CHMP) Safety Working Party (SWP) Questions and answers on the 'Guideline on the limits of genotoxic impurities'

More information

Regenerative medicine in the United Kingdom

Regenerative medicine in the United Kingdom A Social Science Analysis of Regenerative Medicine Regenerative medicine in the United Kingdom Clinical Delivery Policy Briefing February 2017 Clinical delivery.what are the logistical challenges with

More information

Explanatory Note to GVP Module VII

Explanatory Note to GVP Module VII 31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure

More information

ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers

ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers 14 December EMA/CHMP/ICH/320985/2016 Committee for Medicinal Products for Human Use ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions

More information

Explanatory note on general fees payable to the European Medicines Agency

Explanatory note on general fees payable to the European Medicines Agency Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation

More information

Standard operating procedure

Standard operating procedure Title: Audit programmes and internal audits conducted by the Audit Advisory Function Status: Public Document no.: SOP/EMA/0025 Lead author Approver Effective date: 16/10/2017 Name: Edit Weidlich Name:

More information

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Cell and Gene Therapy Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Daniel Stark Head External Supply Cell- and Gene Therapies Development and Manufacturing

More information

EMA pharmacovigilance system manual

EMA pharmacovigilance system manual 13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000

More information

EU Clinical Trial Regulation A view from the Industry

EU Clinical Trial Regulation A view from the Industry Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty

More information

The European Approach on Large Sample Sizes in the context of a PAT Environment

The European Approach on Large Sample Sizes in the context of a PAT Environment The European Approach on Large Sample Sizes in the context of a PAT Environment Dr. Michael Wierer, Deputy Head, European Pharmacopoeia Department, European Directorate for the Quality of Medicines & HealthCare

More information

Academic and Industry Partnerships

Academic and Industry Partnerships Academic and Industry Partnerships Technology Transfer and Scale-Up Stewart Abbot 8 th June 2017 Disclosure Stewart Abbot is an employee and share holder of Fate Therapeutics Inc. Fate Therapeutics Inc.

More information